US 12110334
Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
granted A61KA61K2039/505A61P
Quick answer
US patent 12110334 (Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy) held by The Regents of the University of California expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61P, A61P1/04, A61P31/20